KIO-301 is a small molecule commercialized by Kiora Pharmaceuticals, with a leading Phase II program in Retinitis Pigmentosa (Retinitis). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of KIO-301’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for KIO-301 is expected to reach an annual total of $23 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
KIO-301 (B-203) is under development for the treatment of retinitis pigmentosa. It is administered through intravitreal route. The drug candidate is a small molecule and acts as a reversible photoswitch.
Kiora Pharmaceuticals Overview
Kiora Pharmaceuticals (Kiora), formerly EyeGate Pharmaceuticals, is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company’s pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a potential vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. KIO-101 is a non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (OPRA). Its KIO-201 is a synthetic modified hyaluronic acid (HA) capable of coating the ocular surface and designed to resist degradation under conditions present in the eye. Kiora is headquartered in Salt lake city, Utah, the US.
The operating loss of the company was US$14 million in FY2021, compared to an operating loss of US$8.1 million in FY2020. The net loss of the company was US$13.8 million in FY2021, compared to a net loss of US$8.1 million in FY2020.
For a complete picture of KIO-301’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.